Although some reports find comparable checkpoint expressions between primary and metastatic sites [18], others highlight significant heterogeneity, such as variable TIM-3 and PD-1 levels depending on tumor type and metastatic location [20]. This evidence concerns the gene PDCD1 and neoplasm.